Vertical: Healthcare
Market Size (2019)
$346.37M
Projected (2035)
$1.08B
CAGR (2019–2035)
7.4%
Key Players
10+
This report covers Biotech Procurement in the UK & GCC Market with forecasts from 2019 to 2035. 10 key companies are profiled.
The Biotech Procurement in the UK & GCC Market market is projected to grow at a CAGR of 7.4% from 2019 to 2035.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansINTRODUCTION
The demand for precision medicine and biologics, along with the advancements in biotechnology and R&D innovation, are major factors driving the growth of the UK and GCC biotech procurement market. However, the absence of skilled procurement functions in biotech startups and small laboratories is expected to hinder market expansion. Nevertheless, strategic partnerships, investments, and the integration of artificial intelligence in biotech procurement platforms are anticipated to create lucrative opportunities for industry.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
—
Historical Period
2019 – 2035
Forecast Period
2019 – 2035
Primary Interviews
150+
Historical performance and future projections
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Michael Porter's Five Forces model is a framework to study the UK and GCC biotech procurement market. Strategic business managers trying to gain an edge over competing firms in the UK and GCC biotech procurement market can utilize this model to better comprehend the industry in which the firm operates. The components of each of the forces and the degree of impact of each component in the context of the UK and GCC biotech procurement market have been broken down and analyzed.
PORTER'S FIVE FORCES Analysis: UK and GCC biotech procurement market
Threat of New Entrants
The biotech procurement market in the UK and GCC is experiencing high potential for new entrants due to relatively low barriers to entry in digital, increasing investment in biotech across the region, and government initiatives supporting innovation and healthcare modernization. Particularly in the UAE and Saudi Arabia, ambitious national visions are creating opportunities for startups and tech-driven entrants, intensifying competition and making it easier for agile new players to challenge incumbents.
Bargaining Power of Suppliers
Suppliers in this market such as biotech manufacturers, data providers, and platform technology vendors hold moderate power. While some specialized biotech products may come from a limited number of providers, increasing digitalization and international trade have expanded access to alternative sources. In the GCC, regional efforts to diversify suppliers and encourage local production are balancing the power dynamics, although niche and patented products can still give certain suppliers a strategic advantage.
Threat of Substitutes
The threat of substitutes is high, driven by the availability of alternative procurement methods such as direct purchasing, traditional distributors, or competing digital offering similar services. In addition, broader tech solutions like ERP systems or integrated supply chain may replace the need for specialized biotech procurement, especially if they offer greater scalability or cost-efficiency.
Bargaining Power of Buyers
Buyers, including hospitals, research institutions, and healthcare providers, have high bargaining power due to the increasing number of procurements, rising transparency in pricing, and their ability to switch between service providers. In both the UK and GCC, procurement decisions are heavily influenced by cost-effectiveness and platform reliability, making customer retention difficult and giving buyers strong leverage in negotiations.
Intensity of Rivalry
The biotech procurement platform market is marked by intense rivalry, fueled by rapid technological advancements, increased government and private sector spending in healthcare, and the entrance of global and regional players competing for market share. Both established companies and innovative startups are vying for dominance through pricing strategies, platform features, partnerships, and service quality, creating a highly competitive and fast-evolving landscape.
Financial Analysis of Major Players
Subscription Charges
Based on primary interviews with key stakeholders within the market, it has been identified that the subscription pricing structure for procurement platforms varies significantly based on several critical factors. These factors include the duration of the subscription period, type of account, and the number of users accessing the platform. Typically, billing is conducted on an annual basis, with monthly costs fluctuating in accordance with the user count. Specifically, larger organizations with more extensive user bases tend to benefit from tiered pricing models that reduce per-user costs, whereas smaller organizations may incur higher per-user charges.
Furthermore, it is noteworthy that a considerable segment of UK-based companies adopts alternative pricing strategies, most notably a commission-based model. Under this approach, vendors do not charge upfront subscription fees; instead, they generate revenue through commissions on transactions or procurements facilitated via the platform. This model often aligns incentives towards successful procurement outcomes and may appeal to organizations seeking to minimize fixed costs.
Overall, the market exhibits a diverse landscape of pricing methodologies, influenced by company size, procurement volume, and strategic preferences. The prevalent models include subscription-based pricing, characterized by variable rates depending on usage parameters, and commission-based arrangements, which shift the revenue model from fixed fees to performance-based charges.
SUBSCRIPTION CHARGES BY MAJOR PLAYERS
Company
No. of Users
Average Cost
Amici Procurement
Single User
USD 130 per Month
Multi-Users (For 5 Users)
USD 400 per Month
Prendio LLC
Single User
USD 100 per Month
Multi-Users (For 5 Users)
USD 300 per Month
Quartzy Inc
Single User
USD 50 per Month
Multi-Users (For 5 Users)
USD 200 per Month
Precoro Inc
Single Users/Limited Users
USD 499/999 per Month
Zageno Inc
Single/Multi-Users
1-2% per Transaction Billed
Assay Depot Inc (Scientist.com)
Single/Multi-Users
1-8% per Transaction Billed
Customer Acquisition Cost (CAC)
The Customer Acquisition Cost (CAC) per new customer onboarding onto the biotech platform varies significantly depending on the inclusion of promotional expenditures and the salaries of the sales and marketing teams. To facilitate a comprehensive understanding of these variances, we have compiled a detailed analysis presented in the table below. This table provides the CAC for various prominent biotech procurement platforms, highlighting the factors influencing acquisition costs and enabling informed decision-making for strategic planning and resource allocation.
Customer Acquisition Cost (CAC) for Major Players
Company
Cost Type
Customer Acquisition Cost (CAC)
Amici Procurement
Promotional Cost and Salaries
USD 6,500-8,000
Promotional Cost
USD 2,000
Prendio LLC
Promotional Cost and Salaries
USD 6,000-7,000
Promotional Cost
USD 1,200-1500
Quartzy Inc
Promotional Cost and Salaries
USD 7,000
Promotional Cost
USD 1,500
Precoro Inc
Promotional Cost and Salaries
USD 6,000-6,500
Promotional Cost
USD 1,000-2,000
Zageno Inc
Promotional Cost and Salaries
USD 5,500-6,500
Promotional Cost
USD 1,000
Commission Models for Suppliers
In biotech procurement platforms, commission models for suppliers refer to the ways in which these platforms generate revenue by charging suppliers for their participation or services. Commission models in biotech procurement platforms are designed to align platform revenue with supplier activity, often combining multiple models to optimize monetization while supporting supplier engagement and growth. Common commission models adopted by market players include:
Percentage-Based Commission: The platform charges suppliers a fixed percentage of each transaction or sale made through the platform. For example, if a supplier sells a biotech product worth US$ 10,000, and the commission rate is 5%, the platform earns US$ 500. Players such as Amici Procurement and Zageno follow percentage-based commission model for suppliers.
Flat Fee per Transaction: Suppliers pay a predetermined fixed fee for each transaction, regardless of the transaction size. This model provides predictability for both the platform and suppliers.
Subscription-Based Model: Suppliers pay a recurring subscription fee (monthly, quarterly, or annually) to be listed or to access the platform's services. Additional transaction-based commissions may or may not apply.
Tiered Commission Structures: Commission rates vary based on sales volume or value. For example, a supplier might pay a lower percentage for higher sales volumes, incentivizing larger transactions.
Market estimates by geography (2035)
InsightGlobal leads with $5.21B by 2035.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2019 | 2019 | 2035 | CAGR | SHARE |
|---|---|---|---|---|---|
| Global | $1.80B | $3.05B | $5.21B | 6.9% | 56% |
| UK | $1.45B | $2.44B | $4.13B | 6.7% | 44% |
| Total | $3.25B | $5.49B | $9.34B | 7.4% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Biotech Procurement in the UK & GCC Market covering market dynamics, competitive landscape, and strategic outlook.
The Biotech Procurement in the UK & GCC Market market is projected to reach $1.08B by 2035, growing at 7.4% CAGR.
INTRODUCTION
The demand for precision medicine and biologics, along with the advancements in biotechnology and R&D innovation, are major factors driving the growth of the UK and GCC biotech procurement market. However, the absence of skilled procurement functions in biotech startups and small laboratories is expected to hinder market expansion. Nevertheless, strategic partnerships, investments, and the integration of artificial intelligence in biotech procurement platforms are anticipated to create lucrative opportunities for industry.
Demand for precision medicine and biologics
The rising global demand for precision medicine and biologics is a significant catalyst driving the growth of the biotech procurement market in the UK and the Gulf Cooperation Council (GCC), particularly in the United Arab Emirates (UAE) and Saudi Arabia. This trend is reshaping sourcing priorities, increasing the need for advanced research inputs, and stimulating investment in specialized technologies.
Precision medicine built on targeted therapies tailored to individual genetic profiles requires complex biologic compounds, sophisticated diagnostic tools, and highly customized laboratory supplies. These demands place substantial pressure on procurement systems to deliver high-quality, research-grade resources. In the UK, the alignment of healthcare systems and research institutions with personalized treatment models has led to a growing focus on sourcing advanced biologics and genomic technologies, thereby expanding specialized supplier networks.
A similar transformation is underway in the GCC, where the UAE and Saudi Arabia are making substantial investments in genomics, personalized healthcare, and domestic biomanufacturing. These initiatives are key components of their broader economic diversification and healthcare transformation strategies. For example, in January 2025, King Faisal Specialist Hospital & Research Center (KFSHRC) modernized its Biobank Center to support Saudi Arabia’s precision medicine objectives and align with the innovation goals of Saudi Vision 2030. The upgraded facility enhances the collection and analysis of high-quality biological samples, accelerating research in oncology, cardiovascular conditions, and genetic disorders.
Likewise, in April 2025, the Department of Health – Abu Dhabi (DoH) signed a landmark memorandum of understanding (MoU) during Abu Dhabi Global Health Week. This agreement, formed in collaboration with PureHealth, Khalifa University, Illumina, M42, the Institute for Healthier Living Abu Dhabi (IHLAD), and NYU Abu Dhabi, marks a pivotal step toward advancing precision medicine and next-generation healthcare in the region. The partnership aims to build robust genomic infrastructure and implement population health programs tailored to Emirati and regional needs, leveraging cutting-edge research in genomics, stem cell science, and data-driven healthcare.
These modernization efforts not only improve patient-specific treatment outcomes but also enhance the Kingdom’s and the UAE's positions as global leaders in precision healthcare and biomedical research. They are poised to foster international collaboration, support academic excellence, and drive the development of a sustainable, knowledge-based biotech economy.
As both nations accelerate the development of their biotech infrastructure, procurement platforms are evolving to meet the growing demand for specialized reagents, biologics, and data-driven medical technologies. This evolution is creating a high-value market and stimulating demand for precision-focused suppliers and solutions. In turn, the surge in demand is prompting the adoption of smarter procurement systems and strategic supplier partnerships, enabling the UK, UAE, and Saudi Arabia to enhance clinical innovation, improve health outcomes, and establish themselves as critical players in the global biotech value chain.
Advancements in Biotechnology and R&D Innovation
Advancements in biotechnology and ongoing R&D innovation are fueling significant growth in the global biotech industry, with the UK and GCC regions emerging as key drivers of this expansion. As biotech companies ramp up research in areas such as genomics, personalized medicine, and biopharmaceuticals, there is a corresponding rise in demand for advanced laboratory supplies, including specialized devices and consumables. This surge in R&D activity underscores the need for robust procurement systems that can support high-volume, precision sourcing requirements.
In the UK, strong government support for life sciences and a well-established innovative ecosystem are accelerating this demand, while in the GCC, national strategies and healthcare transformation initiatives are driving substantial investments in biotech infrastructure. Collectively, these dynamics are propelling growth in the regional biotech procurement markets, creating a heightened need for efficient, scalable supply chain solutions that cater to the evolving requirements of cutting-edge research and development.
Strategic partnerships and investments are significantly creating lucrative growth opportunities in the biotech procurement markets in both the UK and GCC countries. In Saudi Arabia, the National Biotechnology Strategy, part of the Kingdom's Vision 2030, is driving the development of a self-sufficient biomanufacturing sector, focusing on vaccines, biologics, and biosimilars. By expanding the national genomic database and fostering local biomanufacturing capabilities, Saudi Arabia is positioning itself as a global leader in healthcare innovation. A notable example of this is the groundbreaking partnership between Saudi agencies and Vertex s, s 2024, w s ’s. This agreement, valued at U 266 million billion audi iyal over five years, is e pected to boost audi rabia’s ene therapy capabilities and attract further international biotech investments, fostering growth in both the domestic and global biotech markets. Further, Saudi Arabia's Ministry of Investment, in 2023, signed two memorandums of understanding during the Global Medical Biotechnology Summit in Riyadh, focusing on strengthening biotechnology and medical cooperation.
These agreements emphasize Saudi Arabia’s commitment to becomin a lobal biotech leader throu h strate ic international collaborations These efforts contribute not only to advancing local biotech industries but also create significant procurement opportunities for foreign biotech companies looking to collaborate with Saudi counterparts. Furthermore, in the UAE, the government's creation of free economic zones like the Dubai Biotechnology and Research Park and Abu Dhabi Global Market play a vital role in attracting international biotech firms. These zones provide incentives such as 100% foreign ownership and tax exemptions, which are essential for driving the growth of the biotech sector. Collaborations with major global pharma companies like AbbVie and Sanofi strengthen the UAE's position as a gateway for biopharma to international markets. A notable partnership, initiated in June 2023, between the Department of Health Abu Dhabi, Eli Lilly, and AbbVie, focuses on clinical research, personalized medicine, and genomics.
These collaborations are poised to create substantial advancements in the U 's biotech landscape and are e pected to drive both mar et ro th and investment in the country’s procurement mar et Also, the increasing focus on areas such as rare diseases, genomics, and personalized medicine, particularly in Saudi Arabia, Qatar, and the UAE, further strengthens the GCC's appeal as a growing hotspot for international biotech investments. The GCC's dynamic biotechnology sector is attracting global players, which leads to expanded procurement opportunities for regional companies and foreign investors alike. Moreover, in the UK, strategic partnerships with the GCC countries are creating significant opportunities for growth in the biotech sector The UK’s participation in international forums li e the World conomic orum in avos, coupled ith its efforts to attract private investments, especially in infrastructure and green energy, is enhancing its biotech profile. The UK also unveiled plans in August 2024 to invest up to USD 527 million into clinical trials and biomanufacturing through the Voluntary Scheme for Branded Medicine Pricing, Access, and Growth (VPAG).
This initiative, supported by the Association of the British Pharmaceutical Industry B I, aims to re uvenate the UK’s clinical trial capabilities and attract international investment, particularly from CC countries. This collaboration is instrumental in fostering innovation, advancing biotech capabilities, and creating significant procurement opportunities in both the UK and GCC markets. Together, these strategic partnerships and investments are driving innovation and market expansion in the biotech procurement sectors of both the UK and GCC. They create lucrative growth opportunities by fostering collaboration, improving healthcare infrastructure, and attracting global investments. These efforts are shaping the future of biopharma in these regions and contributing to the global advancement of industry. The integration of Artificial Intelligence (AI) into biotech procurement platforms is strategically transforming the procurement landscape in the UK and GCC specifically the United Arab Emirates (UAE) and Saudi Arabia by unlocking a new wave of operational efficiency, market intelligence, and cross-border collaboration. As both regions seek to strengthen their positions in the global biotech ecosystem, AI is acting as a critical enabler by automating and optimizing procurement processes, reducing manual inefficiencies, and ensuring real-time decision-making based on predictive analytics.
In the UK, where biotech is a key pillar of the life sciences sector, AI-driven procurement is supporting commercialization strategies, accelerating R&D supply chain cycles, and facilitating precision sourcing from global suppliers. This aligns with the UK's broader strategy to maintain a leadership role in biotech innovation post-Brexit. Currently, in the GCC, where the UAE and Saudi Arabia are aggressively pursuing healthcare transformation under Vision 2030 and similar strategic frameworks, AI-enabled procurement platforms may empower domestic manufacturing agendas by improving supplier visibility, enhancing traceability, and enabling data-driven localization of high-value biotech inputs. Moreover, in March 2025, Prendio-BioProcure unveiled a new suite of generative AI, real-time analytics, and workflow automation capabilities designed to enhance its market-leading life sciences procure-to-pay (P2P) platform. The launch addresses critical inefficiencies fa
Absence of skilled procurement function in biotech startups and small labs
The absence of a skilled procurement function in biotech startups and small labs is undermining cost optimization, supply chain resilience, and scalability, directly constraining the growth trajectory of the UK and GCC biotech procurement markets. Startups often lack procurement professionals with the expertise to negotiate favorable supplier contracts, secure bulk pricing, or align purchasing strategies with R&D timelines, eroding margins and delaying product development cycles.
In the UK, where biotech innovation clusters like the Golden Triangle drive sector growth, fragmented procurement practices lead to inflated costs for specialized reagents, lab equipment, and outsourced services, reducing return on investment (ROI) and deterring investor confidence. Similarly, in the GCC where governments prioritize biotech diversification under initiatives like Saudi Vision 2030 inefficient procurement frameworks hinder access to global suppliers, creating bottlenecks in sourcing advanced technologies and compliance-certified materials.
This operational inefficiency diminishes agility in responding to market demands, stifling scalability and delaying commercialization. Furthermore, inadequate risk management in procurement exposes startups to supply chain disruptions, exacerbating financial volatility in capital-intensive biotech ventures. For both regions, the gap in procurement expertise not only limits local market expansion but also weakens global competitiveness, as rivals leverage strategic sourcing to accelerate innovation and reduce time-to-market. Addressing this deficit through targeted talent development, partnerships with procurement consultants, or shared-service alliances could unlock cost efficiencies, stabilize supply chains, and position the UK and GCC as leaders in the global biotech economy.
Strategic partnerships and investments are significantly creating lucrative growth opportunities in the biotech procurement markets in both the UK and GCC countries. In Saudi Arabia, the National Biotechnology Strategy, part of the Kingdom's Vision 2030, is driving the development of a self-sufficient biomanufacturing sector, focusing on vaccines, biologics, and biosimilars. By expanding the national genomic database and fostering local biomanufacturing capabilities, Saudi Arabia is positioning itself as a global leader in healthcare innovation. A notable example of this is the groundbreaking partnership between Saudi agencies and Vertex Pharmaceuticals, signed in December 2024, which aims to enhance the country’s gene therapy production. This agreement, valued at USD 266 million (1 billion Saudi Riyal) over five years, is expected to boost Saudi Arabia’s gene therapy capabilities and attract further international biotech investments, fostering growth in both the domestic and global biotech markets.
Further, Saudi Arabia's Ministry of Investment, in 2023, signed two memorandums of understanding during the Global Medical Biotechnology Summit in Riyadh, focusing on strengthening biotechnology and medical cooperation. These agreements emphasize Saudi Arabia’s commitment to becoming a global biotech leader through strategic international collaborations. These efforts contribute not only to advancing local biotech industries but also create significant procurement opportunities for foreign biotech companies looking to collaborate with Saudi counterparts.
Furthermore, in the UAE, the government's creation of free economic zones like the Dubai Biotechnology and Research Park and Abu Dhabi Global Market play a vital role in attracting international biotech firms. These zones provide incentives such as 100% foreign ownership and tax exemptions, which are essential for driving the growth of the biotech sector. Collaborations with major global pharma companies like AbbVie and Sanofi strengthen the UAE's position as a gateway for biopharma to international markets. A notable partnership, initiated in June 2023, between the Department of Health Abu Dhabi, Eli Lilly, and AbbVie, focuses on clinical research, personalized medicine, and genomics. These collaborations are poised to create substantial advancements in the UAE's biotech landscape and are expected to drive both market growth and investment in the country’s procurement market.
Also, the increasing focus on areas such as rare diseases, genomics, and personalized medicine, particularly in Saudi Arabia, Qatar, and the UAE, further strengthens the GCC's appeal as a growing hotspot for international biotech investments. The GCC's dynamic biotechnology sector is attracting global players, which leads to expanded procurement opportunities for regional companies and foreign investors alike.
Moreover, in the UK, strategic partnerships with the GCC countries are creating significant opportunities for growth in the biotech sector. The UK’s participation in international forums like the World Economic Forum in Davos, coupled with its efforts to attract private investments, especially in infrastructure and green energy, is enhancing its biotech profile. The UK also unveiled plans in August 2024 to invest up to USD 527 million into clinical trials and biomanufacturing through the Voluntary Scheme for Branded Medicine Pricing, Access, and Growth (VPAG). This initiative, supported by the Association of the British Pharmaceutical Industry (ABPI), aims to rejuvenate the UK’s clinical trial capabilities and attract international investment, particularly from GCC countries. This collaboration is instrumental in fostering innovation, advancing biotech capabilities, and creating significant procurement opportunities in both the UK and GCC markets.
Together, these strategic partnerships and investments are driving innovation and market expansion in the biotech procurement sectors of both the UK and GCC. They create lucrative growth opportunities by fostering collaboration, improving healthcare infrastructure, and attracting global investments. These efforts are shaping the future of biopharma in these regions and contributing to the global advancement of industry.
Integration of Artificial Intelligence in Biotech Procurement Platforms
The integration of Artificial Intelligence (AI) into biotech procurement platforms is strategically transforming the procurement landscape in the UK and GCC specifically the United Arab Emirates (UAE) and Saudi Arabia by unlocking a new wave of operational efficiency, market intelligence, and cross-border collaboration. As both regions seek to strengthen their positions in the global biotech ecosystem, AI is acting as a critical enabler by automating and optimizing procurement processes, reducing manual inefficiencies, and ensuring real-time decision-making based on predictive analytics.
In the UK, where biotech is a key pillar of the life sciences sector, AI-driven procurement is supporting commercialization strategies, accelerating R&D supply chain cycles, and facilitating precision sourcing from global suppliers. This aligns with the UK's broader strategy to maintain a leadership role in biotech innovation post-Brexit. Currently, in the GCC, where the UAE and Saudi Arabia are aggressively pursuing healthcare transformation under Vision 2030 and similar strategic frameworks, AI-enabled procurement platforms may empower domestic manufacturing agendas by improving supplier visibility, enhancing traceability, and enabling data-driven localization of high-value biotech inputs.
Moreover, in March 2025, Prendio-BioProcure unveiled a new suite of generative AI, real-time analytics, and workflow automation capabilities designed to enhance its market-leading life sciences procure-to-pay (P2P) platform.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 109 companies operating in the Biotech Procurement in the UK & GCC Market market, including revenue, employee count, and market positioning where available.
Showing 109 of 109 companies
11 interactive charts drawn from the Biotech Procurement in the UK & GCC Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Biotech Procurement in the UK & GCC By Country
Biotech Procurement in the UK & GCC By End User
Biotech Procurement in the UK & GCC By Solutions
Biotech Procurement in the UK & GCC By Region
Biotech Procurement in the UK & GCC By Others
Biotech Procurement in the UK & GCC By Cro And Cdmo
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
